Skip to main content
. 2015 Apr 2;3(2):E251–E257. doi: 10.9778/cmajo.20140095

Figure 2:

Figure 2:

Respondents’ level of comfort (measured on a 10-point scale) with prescribing cannabinoids for all indications and for chronic noncancer pain (CNCP) specifically. Data were missing for 6.0%–6.6% of respondents. Error bars = standard deviations.